Id: CBI_2382 | Pages: 318 | Format : PDF | Published : | Author : Amit Sati | Category : Pharmaceuticals
The aphakia market size is growing with a CAGR of 11.6% during the forecast period (2025-2032), and the market is projected to be valued at USD 4,149.75 Million by 2032 from USD 1,726.04 Million in 2024. Additionally, the market value for the 2025 attributes to USD 1,920.72 Million.
Aphakia is the medical condition referring to absence of the lens of the eye. The symptoms in this condition includes blurred vision, color precipitation, difficulty in focusing, and others. It is mainly of two types, congenital and acquired. Further, congenital aphakia is present at birth while acquired aphakia is caused due to surgical removal, trauma, or other medical conditions. This condition is treated with surgery, contact lenses, spectacles, and others. Healthcare facilities such as hospitals, ophthalmic clinics, and others are providing advanced diagnosis and treatment options for aphakia. Moreover, advancements in treatment options is enhancing the management of this condition among the patients further driving the market expansion.
The cataract is a medical condition in which the lens of the eye becomes cloudy, resulting in blurred vision. In the treatment of cataract, the natural lens are removed during surgery to treat the clouded lens which leads to aphakia. The prevalence of cataract is high due to diabetes, growing population, smoking and poor nutrition further driving the market.
Thus, the high prevalence of cataract is leading to aphakia market demand.
Rising awareness about eye health is a major driver in the market. Private hospitals and eye care centers are launching campaigns to spread awareness about eye-related conditions including aphakia. Moreover, government bodies and medical associations are providing online sources to inform the prospective patients about this condition, its symptoms and diagnostic methods.
Hence, rising awareness about eye health is leading to aphakia market expansion.
Regulatory approvals are significantly restraining the market due to stringent requirements for the approval of intraocular lenses and contact lenses. Authorities such as United States Food and Drug Administration, European Medicines Agency (EMA) impose rigorous testing and documentation requirement for these lenses before it is approved for clinical use. These regulations ensure that the intraocular lenses and contact lenses do not cause harm, function effectively in treatment and meet the required quality standards. The approval process involves multiple stages, including preclinical trials, testing, biocompatibility evaluations and clinical trials, which are time-intensive and costly. It typically causes delays due to lengthy evaluations of additional requirements for compliance. Thus, stringent regulatory approvals are constraining the market demand due to increased cost and limited availability of advanced technology.
An intraocular lens is a lens implanted in the eye through the surgery for the treatment of aphakia. It improves blurred vision and ability to focus in the patients. Innovations in design and haptics are increasing the applicability of intraocular lens. Advanced design provides crisp vision and reduces glare & posterior capsular opacification. Unique haptics provide superior axial and rotational stability in the lens. Moreover, companies are also developing intraocular lenses with advanced material.
Thus, new product innovations in intraocular lens are expected to create aphakia market opportunities.
Based on type, the market is categorized into congenital and acquired.
Trends in Type
The acquired segment accounted for the largest market share in the year 2024.
The congenital segment is expected to grow at the fastest CAGR over the forecast period.
Based on treatment, the market is categorized into surgery, contact lenses, spectacles, and others.
Trends in Treatment
The surgery segment accounted for the largest market share in the year 2024.
The contact lenses segment is expected to grow at the fastest CAGR over the forecast period.
Based on end-use, the market is categorized into hospitals, ophthalmic clinics, and others.
Trends in End-Use
The hospitals segment accounted for the largest market share of 63.19% in the year 2024.
The ophthalmic clinics segment is expected to grow at the fastest CAGR over the forecast period.
The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2024, North America accounted for the highest market share at 41.23% and was valued at USD 711.65 Million and is expected to reach USD 1,611.38 Million in 2032. In North America, United States accounted for the highest market share of 71.33% during the base year of 2024. The aphakia market share of the North America region is major due to technological advancements. Technological advancements in contact lenses and intraocular lens have enhanced the treatment options for aphakia. Moreover, companies are developing intraocular lens with advanced features for easy implantation further driving the market.
Thus, North America is leading in the market due to technological advancements and advanced healthcare industry as per analysis.
Asia-pacific is expected to witness the fastest CAGR of 13.2% over the forecast period of 2025-2032. According to aphakia market analysis, the Asia Pacific region is growing rapidly driven by rising prevalence of the ophthalmic diseases. Countries such as China, India, Japan, and South Korea are major contributors in the market due to growing cases of cataracts and glaucoma. The increasing number of hospitals and ophthalmic clinics is further driving the adoption of surgery and spectacles in the treatment of ophthalmic diseases. Hence, the aphakia market share of Asia Pacific is experiencing rapid growth through rising prevalence of ophthalmic diseases and increasing number of hospitals & ophthalmic clinics.
According to aphakia market analysis, Europe region is experiencing steady growth in the market driven by increasing health expenditure. The region is well developed with modern diagnostic technology and skilled ophthalmologists along with digital healthcare infrastructure. The government in the region is also investing in research and development of contact lenses with advanced features for easy applicability. It is further leading to aphakia market expansion in the region.
The Middle East and Africa region is experiencing gradual demand in the market, driven by increasing awareness about eye health and improving healthcare industry. Countries such as Dubai, UAE, and South Arica are major contributors in the market where advanced hospitals and government organizations provide access to advanced treatments for aphakia. Further, the ophthalmic clinics in the region offer diagnostic methods such as genetic testing and complete eye exam as per analysis.
As per analysis, the market in Latin America is driven by rising disposable income and growing population. Countries such as Brazil, Mexico and Argentina are major contributors in the region due to modern healthcare infrastructure. The rise of diagnostic centers and private hospitals has significantly impacted the availability of advanced treatment options for eye-related conditions. Additionally, patients in the region prefer contact lenses due to easy applicability and improved vision.
The aphakia industry is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D) and product innovation to hold a strong position in the global aphakia market. Key players in aphakia industry include-
Report Attributes | Report Details |
Study Timeline | 2019-2032 |
Market Size in 2032 | USD 4,149.75 Million |
CAGR (2025-2032) | 11.6% |
By Type |
|
By Treatment |
|
By End-Use |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
In 2024, the aphakia market is USD 1,726.04 million.
Asia Pacific is the fastest-growing region in the aphakia market.
Type, Treatment, and End-Use are covered in the aphakia market.
Alcon Inc. (Switzerland), Johnson & Johnson Services, Inc. (United States), and Bausch & Lomb Incorporated. (Canada) are some of the major players in the market.